vs
Side-by-side financial comparison of American Express (AXP) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $18.9M, roughly 1.2× American Express). American Express runs the higher net margin — 15.7% vs -416.2%, a 431.9% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 11.4%). Over the past eight quarters, Intellia Therapeutics, Inc.'s revenue compounded faster (-10.8% CAGR vs -95.6%).
American Express Company, together with its subsidiaries, provides charge and credit payment card products, and travel-related services worldwide. The company operates through three segments: Global Consumer Services Group, Global Commercial Services, and Global Merchant and Network Services. Its products and services include payment and financing products; network services; accounts payable expense management products and services; and travel and lifestyle services. The company's products an...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
AXP vs NTLA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $23.0M |
| Net Profit | $3.0M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | — | -428.9% |
| Net Margin | 15.7% | -416.2% |
| Revenue YoY | 11.4% | 78.8% |
| Net Profit YoY | 15.0% | 25.7% |
| EPS (diluted) | — | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | $23.0M | ||
| Q3 25 | $10.4B | $13.8M | ||
| Q2 25 | $10.3B | $14.2M | ||
| Q1 25 | $9.6B | $16.6M | ||
| Q4 24 | $10.0B | $12.9M | ||
| Q3 24 | $9.7B | $9.1M | ||
| Q2 24 | $9.8B | $7.0M |
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | $-95.8M | ||
| Q3 25 | $2.9B | $-101.3M | ||
| Q2 25 | $2.9B | $-101.3M | ||
| Q1 25 | $2.6B | $-114.3M | ||
| Q4 24 | $2.2B | $-128.9M | ||
| Q3 24 | $2.5B | $-135.7M | ||
| Q2 24 | $3.0B | $-147.0M |
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | -428.9% | ||
| Q3 25 | 36.7% | -808.9% | ||
| Q2 25 | 34.4% | -772.2% | ||
| Q1 25 | 34.6% | -726.6% | ||
| Q4 24 | 27.7% | -1059.9% | ||
| Q3 24 | 33.0% | -1589.0% | ||
| Q2 24 | 38.6% | -1998.6% |
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | -416.2% | ||
| Q3 25 | 27.9% | -735.2% | ||
| Q2 25 | 28.0% | -710.8% | ||
| Q1 25 | 26.8% | -687.6% | ||
| Q4 24 | 21.8% | -1001.2% | ||
| Q3 24 | 25.8% | -1489.5% | ||
| Q2 24 | 30.7% | -2112.6% |
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | $-0.81 | ||
| Q3 25 | $4.14 | $-0.92 | ||
| Q2 25 | $4.08 | $-0.98 | ||
| Q1 25 | $3.64 | $-1.10 | ||
| Q4 24 | $3.04 | $-1.27 | ||
| Q3 24 | $3.49 | $-1.34 | ||
| Q2 24 | $4.15 | $-1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $449.9M |
| Total DebtLower is stronger | $60.4M | — |
| Stockholders' EquityBook value | $34.0M | $671.4M |
| Total Assets | $308.9M | $842.1M |
| Debt / EquityLower = less leverage | 1.78× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | $449.9M | ||
| Q3 25 | $1.3B | $511.0M | ||
| Q2 25 | $197.0M | $459.7M | ||
| Q1 25 | $261.0M | $503.7M | ||
| Q4 24 | $221.0M | $601.5M | ||
| Q3 24 | $120.0M | $658.1M | ||
| Q2 24 | $188.0M | $691.1M |
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | $671.4M | ||
| Q3 25 | $32.4B | $748.4M | ||
| Q2 25 | $32.3B | $715.3M | ||
| Q1 25 | $31.2B | $779.9M | ||
| Q4 24 | $30.3B | $872.0M | ||
| Q3 24 | $29.7B | $962.6M | ||
| Q2 24 | $29.5B | $971.1M |
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | $842.1M | ||
| Q3 25 | $297.6B | $925.3M | ||
| Q2 25 | $295.6B | $898.9M | ||
| Q1 25 | $282.2B | $986.2M | ||
| Q4 24 | $271.5B | $1.2B | ||
| Q3 24 | $271.0B | $1.2B | ||
| Q2 24 | $272.2B | $1.2B |
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-69.3M |
| Free Cash FlowOCF − Capex | — | $-69.4M |
| FCF MarginFCF / Revenue | — | -301.6% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | $-69.3M | ||
| Q3 25 | $6.2B | $-76.9M | ||
| Q2 25 | $4.4B | $-99.6M | ||
| Q1 25 | $4.8B | $-148.9M | ||
| Q4 24 | $5.8B | $-85.2M | ||
| Q3 24 | $-1.8B | $-84.8M | ||
| Q2 24 | $4.5B | $-58.2M |
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | $-69.4M | ||
| Q3 25 | $5.6B | $-76.9M | ||
| Q2 25 | $3.7B | $-99.9M | ||
| Q1 25 | $4.3B | $-149.7M | ||
| Q4 24 | $5.3B | $-86.2M | ||
| Q3 24 | $-2.3B | $-86.1M | ||
| Q2 24 | $4.0B | $-59.2M |
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | -301.6% | ||
| Q3 25 | 53.6% | -558.2% | ||
| Q2 25 | 36.3% | -701.0% | ||
| Q1 25 | 45.0% | -900.1% | ||
| Q4 24 | 53.1% | -669.4% | ||
| Q3 24 | -23.3% | -945.2% | ||
| Q2 24 | 40.4% | -850.9% |
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.5% | ||
| Q3 25 | 6.3% | 0.2% | ||
| Q2 25 | 6.0% | 1.7% | ||
| Q1 25 | 4.5% | 4.4% | ||
| Q4 24 | 5.0% | 7.6% | ||
| Q3 24 | 4.7% | 14.0% | ||
| Q2 24 | 5.8% | 14.5% |
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
